BusinessWeek for June 6 features Judah Folkman in its Voices of Innovation series because he "pioneered a new treatment: starve the tumor." The article goes on to note: "In 1998 media reports trumpeted these early results as cancer cures -- leading to bitter disappointment when endostatin proved hard to make. But with the success of Avastin and other new drugs, Folkman has been vindicated."
EntreMed could not ask for a better investor/partner!CELG is the single largest shareholder in EntreMed.
Celgene (CELG ): Reiterates 4 STARS (buy) Analyst: Frank DiLorenzo, CFA )
Novartis gets the FDA okay for Focalin XR to treat attention deficit hyperactivity disorder. Celgene is entitled to royalties. We think Celgene's guidance for $60 million in Ritalin-related royalties for 2005 is achievable. We expect approval for Thalomid to treat multiple myeloma and Revlimid to treat myelodysplastic syndrome patients with 5q chromosomal deletion by 2005 end. We see 2005 and 2006 earnings per share at 56 cents and 94 cents. Based on net present value analysis, our 12-month target price is $50. We think Celgene's 1.4 times p-e-to-growth is attractive, on our 2006 earnings per share and 30.5% earnings per share growth estimates.